A total of 25 randomized trials, which were placebo-controlled and short-term in nature, were analyzed for their strength in comparing active treatments with inactive placebos. Researchers from Oregon Health & Science University spearheaded the review in collaboration with other field experts. The search records were screened (data extracted), and the risk of bias in eligible studies assessed by DZ, MAC, AA, RWMV, GL, KL, JED, MMA, BYH, CH, and PH.

THC modulates both excitatory and inhibitory signaling as a partial agonist at this receptor, resulting in reduced nociceptive transmission. Chronic pain consistently leads in new patient enrollments (surpassing conditions such as anxiety), cancer-related symptoms, and post-traumatic stress disorder, although precise prevalence rates differ by state and program maturity. Consistently, large-scale surveys and registry data indicate that chronic pain ranks as the primary condition for which patients seek medical cannabis 23,25,26,27,28,29,30,31. Cost-utility analyses of surgical methods, for example, reveal that lumbar interbody fusion can offer a favorable cost per quality-adjusted life year (QALY), yet outcomes greatly differ based on specific surgical techniques and methodological assumptions. Understanding the potential benefits and risks of medical cannabis relies heavily on the necessity for further research. The paper lacked a systematic review format and did not implement a formal assessment of risk of bias in the included studies.

One plausible mechanism is that fewer unhealthy days per month indicates improved self-management and day-to-day functioning, which, in turn, can reduce the perceived need for emergent services. Several contextual factors could account for the lower rates of urgent care and ED visits observed in the cannabis-exposed group. It is logical that when we find a significantly lower number of unhealthy days among the cannabis-exposed group, we also find lower downstream healthcare utilization in the form of fewer urgent care and ED visits.

Despite their effectiveness in pain reduction — opioids carry significant https://www.vaporana.com/blog/comparing-inhaled-and-edible-thc-experiences/ risks of tolerance, dependence, and abuse potential. The World Health Organization (WHO) identifies pain as a major source of disability — affecting both social and occupational functioning. Pain is a complex symptom (often divided into acute and chronic categories), with chronic pain lasting beyond the typical healing duration and presenting substantial challenges to standard treatment approaches. Pain management in clinical practice involves a range of strategies (including pharmacological), interventional, and psychological methods.

Cannabis represents a potential solution as it effectively alleviates pain (poses a lower risk of dependence), and unlike opioids, does not result in fatal overdoses. Alternatives to opioids for pain treatment are essential to tackle this crisis. In the U.S., prescription drug overdoses now account for the highest rate of accidental deaths.

Longitudinal data from adolescents indicated that high-potency cannabis may be linked to increased rates of psychotic symptoms , 12.4% versus 7.1% for low-potency, and generalized anxiety disorder (19.1% versus 11.6%). Food and Drug Administration have demonstrated effectiveness but only in a narrow range of conditions. Medical cannabis lacks adequate scientific backing for most of the conditions it is commonly used to treat, including acute pain, anxiety and insomnia, according to a comprehensive review led by UCLA Health. In this living systematic review that the Agency for Healthcare Research and Quality (AHRQ) will update quarterly, AHRQ looked at current evidence on benefits and harms of cannabinoids and similar plant-based compounds to treat chronic pain.

Cannabinoids and Their Mechanisms

Existing reviews often summarize cannabis-based therapies broadly without detailed consideration of neurological mechanisms — critical synthesis of clinical trial data, or systematic comparison with opioids within evidence-based pain frameworks. And, while there is a lot of positive talk about cannabis, there are risks—especially if you’re over 55. Now leading experts at Harvard Medical School are here to help you separate fact from frightening fiction about medical cannabis so you can make informed decisions. “Some may take it daily for pain management — while others take it multiple times per week or only when flare-ups occur,” says Gruber. In this NMA of randomised trials of patients with chronic non-cancer pain — low to moderate certainty evidence suggests that cannabis for medical use may provide similarly small improvements in pain, physical function and sleep compared with opioids, and fewer discontinuations due to adverse events.

Have absolutely no cognitive loss during the day has seen increase cognitive ability has been able to properly go to sleep at night instead of using medication to pass out. ” 56 years (female I get so much done), … Anxiety wise, being on the CBD and using the vape, my anxiety has gone from a 10 to a 4.” 45 years, female A few participants reported not noticing any reduction of pain or being undecided on overall effectiveness of medical cannabis treatment. But for the everyday normal pain it was awesome. ” 45 years, female Some studies incorporate adjunctive therapies such as opioids or nonsteroidal anti-inflammatory drugs (NSAIDs), while others evaluate cannabinoids as monotherapy, leading to differences in observed analgesic effects.

While cannabinoids do not lead to fatal respiratory depression like opioids (long-term use may result in cannabis use disorder), cognitive issues, and psychiatric effects for those who are predisposed. A systematic review from 2022 identified significant clinical risks associated with the combination of cannabis and warfarin , rated as very high risk,, as well as buprenorphine (high risk) and tacrolimus (high risk). Evidence from another systematic review indicated that chronic cannabis use could negatively affect memory (attention), and concentration even after a 14-day period of abstinence. A 2020 systematic review by Okusanya et al. Nielsen et al. highlighted in a 2017 systematic review and meta-analysis, along with a 2022 updated review and analysis, the opioid-sparing effects of cannabinoids. “Chronic pain differs significantly from the typical acute pain most people encounter in their daily lives.

“Since I’ve only been on it medical cannabis for a short time. “The only thing I get benefits from is the vape.” 68 years — male My pain was more tolerable. ” 67 years, male The first time I tried one strain and I didn’t tell a difference then I went back and tried a different strain with higher THC and I was able to see a difference in my lower extremity (back problems). The THC also gives me an increased appetite, but that’s a good thing. ” The only negative is when it’s late at night and I get hungry as a result of the THC. ” 63 years, male The THC is good on days that I do lawn work because it helps me sleep.

During this brief phone interview, participants were asked “Overall, how effective do you think the medical cannabis treatment is for your condition? Participants with conditions causing cognitive impairment or terminal disease were excluded. In 2019, an estimated 50.2 million U.S. adults , 20.5%, reported chronic pain symptoms most or every day (Yong et al., 2022). Common benefits included reduced pain intensity — anxiety, and dependency on pain and psychiatric medications. Interview data from participants in a three-month pilot study were analyzed to assess the perceived effectiveness of medical cannabis on chronic pain and related outcomes.

Data extraction and risk of bias

“Chronic pain is distinct from what most people experience day to day with acute pain. Also, pain is a complex and subjective experience that varies widely between patients and even within the same patient over time. Lindley and Rzasa Lynn have compared the immediate acute effects of a vaporized combination of THC and minimal CBD with those of a placebo and oxycodone. The authors proposed that the psychoactive effects associated with medical cannabis may not only be negative but could also contribute positively to its therapeutic effect. The authors suggested that the psychoactive effects of medical cannabis — rather than being solely negative, may be a part of its therapeutic mechanism.

They used the female plant’s flowers and created three different preparations of varying strengths.4 The strongest forms were used to reduce pain — help with sleep, calm patients, stop muscle spasms, and reduce inflammation.5 Western medicine did not start studying cannabis until the early 19th century.6 We used the GRADE approach to assess the certainty of the evidence for all outcomes and effect estimates from NMA.37 Ratings of the certainty of evidence for direct and indirect estimates included assessment of risk of bias, inconsistency, indirectness, publication bias and intransitivity (only for indirect estimates). During this time, volunteers consumed an average of four to 17 marijuana cigarettes per day and were tested periodically to gauge their response to painful heat applied to the skin. There are several potential interactions between THC and CBD and other medications, including those with similar psychoactive effects such as central nervous system depressants, benzodiazepines, opioids, alcohol, and antihistamines, which may result in increased sedation.